Psyence Biomedical announces milestone in natural ibogaine HCl production

Psyence Biomedical (PBM) Ltd announced that through its investment in PsyLabs, Psyence BioMed has become the first Nasdaq-listed company to produce GMP-compliant, high-purity ibogaine hydrochloride derived from a naturally extracted, ethically sourced supply in Africa. Ibogaine HCl is the purified, stabilised, crystalline salt form of ibogaine used in clinical and therapeutic settings and represents the standard pharmaceutical format for this compound. Conversion to the hydrochloride salt improves stability, solubility, purity, and dosing precision, aligning the material with regulated medical, research, and pharmaceutical development requirements. “The successful production of GMP-compliant Ibogaine HCl represents an important advancement for Psyence BioMed and our vertically integrated strategy,” said Jody Aufrichtig, CEO of Psyence BioMed. “This achievement strengthens our manufacturing and quality capabilities and supports our long-term objective of advancing nature-derived psychedelic compounds through responsible, regulated development pathways.” With a cash balance of $12M, no debt, a Phase 2b psilocybin clinical trial underway, and the successful production of GMP-grade ibogaine HCl, Psyence BioMed said it is well positioned entering 2026 to advance its strategic priorities and expand its leadership in vertically integrated, nature-derived psychedelic therapeutics.